Astrid Murumägi

Precision Systems Medicine
Senior Researcher, Institute for Molecular Medicine Finland

Phone+358504151680, +358294125765
Emailastrid.murumagi@helsinki.fi

PL 20 (Tukholmankatu 8)
00014
Finland

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Astrid Murumägi is a senior scientist at the Kallioniemi group. She received her PhD in Molecular Immunology at the University of Tampere. During her postdoctoral training she transitioned to systems biology and genomics by joining Prof. Olli Kallioniemi´s team at FIMM in 2009. Her work is focused on applying systems medicine in cancer research. She is involved in the FIMM Grand Challenge on Individualized Systems Medicine program. More specifically, she is responsible for ovarian cancer and melanoma functional precision medicine projects, where patient-derived cancer cells are used for comprehensive drug sensitivity testing and molecular profiling to identify best treatment strategies for patients. In addition she is involved in several collaboration projects where the drug testing platform has been applied to uncover novel drug vulnerabilities in cancer cells.

Fields of Science

3111 Biomedicine
318 Medical biotechnology
3122 Cancers

International and National Collaboration Publications and projects within past five years.

Publications

25 Article
7 Meeting Abstract
1 Review Article

Anagrelide for Gastrointestinal Stromal Tumor

Pulkka, O-P., Gebreyohannes, Y. K., Wozniak, A., Mpindi, J-P., Tynninen, O., Icay, K., Cervera, A., Keskitalo, S., Murumägi, A., Kulesskiy, E., Laaksonen, M., Wennerberg, K., Varjosalo, M., Laakkonen, P., Lehtonen, R., Hautaniemi, S., Kallioniemi, O., Schöffski, P., Sihto, H. & Joensuu, H., 1 Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1676-1687 12 p.

Research output: Contribution to journal › Article › Scientific › peer-review

Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

Murumagi, A., Ungureanu, D., Khan, S., Hirasawa, A., Arjama, M., Valimaki, K., Mikkonen, P., Niininen, W., Kumar, A., Eldfors, S., Pellinen, T., Pietiainen, V., Magi, A., Koivisto-Korander, R., Tapper, J., Loukovaara, M., Aittokallio, T., Butzow, R. & Kallioniemi, O., Jul 2019, In : Cancer Research. 79, 13, 2 p.

Research output: Contribution to journal › Meeting Abstract › Research › peer-review

Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting

Karvonen, H., Perttila, R., Niininen, W., Hautanen, V., Barker, H., Murumagi, A., Heckman, C. A. & Ungureanu, D., 25 Apr 2019, In : Oncogene. 38, 17, p. 3288-3300 13 p.

Research output: Contribution to journal › Article › Scientific › peer-review

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

Sveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., Tabernero, J., Guinney, J., Palmer, H. G., Nesbakken, A., Kallioniemi, O., Dienstmann, R. & Lothe, R. A., 15 Feb 2018, In : Clinical Cancer Research. 24, 4, p. 794-806 13 p.

Research output: Contribution to journal › Article › Scientific › peer-review

Open Access

File